港股異動丨復星醫藥漲7.75% 控股股東增持計劃已累計增持0.28%股份
格隆匯3月24日丨復星醫藥(2196.HK)漲7.75%,報22.25港元,總市值570.24億港元。

復星醫藥上週公佈於控股股東增持計劃實施進展,截至2020年3月18日,此次增持計劃期限已過半。2019年9月19日至2020年3月18日期間,復星高科技通過上海證券交易所交易系統(含港股通)累計增持公司711.65萬股H股股份,累計增持金額摺合人民幣約14898.94萬元,累計增持股份比例佔截至公告日公司已發行股份總數(即2,562,898,545股)的約0.28%。
此外,復星醫藥近日獲納恆生滬深港通生物科技50指數,並位列該指數比重最高的10只成份股之一。對於入選,復星醫藥表示,未來,公司將繼續秉承持續創新,樂享健康的品牌理念,堅持內生式增長、外延式擴張、整合式發展的戰略發展路徑,進一步提升自身創新研發能力、持續推進國際化進程,為股東和投資者創造更多價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.